Q4 25 EPS
$0.46
MISS 17.95%
Est. $0.56
Q4 25 Revenue
$874.6M
BEAT +4.73%
Est. $835.0M
vs S&P Since Q4 25
-15.9%
TRAILING MARKET
BMRN -8.1% vs S&P +7.8%
Full Year 2025 Results
FY 25 EPS
$3.15
FY 25 Revenue
$3.22B
Market Reaction
Did BMRN Beat Earnings? Q4 2025 Results
BioMarin closed out 2025 with a quarter defined as much by strategic upheaval as by underlying momentum, as Q4 revenue climbed 17% year-over-year to $874.57 million while non-GAAP diluted EPS landed at $0.46, a figure cut roughly in half from the pri… Read more BioMarin closed out 2025 with a quarter defined as much by strategic upheaval as by underlying momentum, as Q4 revenue climbed 17% year-over-year to $874.57 million while non-GAAP diluted EPS landed at $0.46, a figure cut roughly in half from the prior-year period largely because of the voluntary withdrawal of gene therapy ROCTAVIAN from the market, which triggered approximately $240 million in charges including a $119 million inventory write-off that flowed directly through cost of sales. VOXZOGO remained the topline engine, growing 31% in the quarter and 26% for the full year, while PALYNZIQ delivered a standout 25% Q4 gain within Enzyme Therapies. Looking ahead, BioMarin guided 2026 total revenues of $3.33 billion to $3.42 billion with non-GAAP diluted EPS of $4.95 to $5.15, a range that excludes contributions from the pending Amicus Therapeutics acquisition, a deal that shareholders have already approved and that is expected to close in Q2 2026, adding Galafold and Pombiliti to the rare disease portfolio.
Key Takeaways
- • VOXZOGO revenue grew 31% Y/Y in Q4 driven by new patients initiating therapy across all regions and timing of large government orders, primarily in Latin America
- • Enzyme Therapies Q4 revenue increased 13% Y/Y driven by increased patient demand in all regions and timing of large government orders
- • PALYNZIQ delivered 25% Q4 and 22% full-year Y/Y revenue growth
- • Markets outside the U.S. drove approximately 73% of VOXZOGO revenue in full-year 2025
- • Strong patient demand across the portfolio fueled 13% Y/Y full-year total revenue growth
BMRN YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
BMRN Revenue by Segment
With YoY comparisons, source: SEC Filings
“In 2025, operational excellence led to strengthening financial results, including double-digit topline growth, strong profitability and increasing cash flow. We also advanced multiple medicines in our pipeline and closed the year by announcing the acquisition of Amicus.”
— Alexander Hardy, Q4 2025 Earnings Press Release
BMRN Earnings Trends
BMRN vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BMRN EPS Trend
Earnings per share: estimate vs actual
BMRN Revenue Trend
Quarterly revenue: estimate vs actual
BMRN Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $0.91 | $0.76 | -16.86% | $766.2M | +1.93% |
| Q4 25 MISS FY | $0.56 | $0.46 | -17.95% | $874.6M | +4.73% |
| FY Full Year | — | $3.15 | — | $3.22B | — |
| Q3 25 MISS | $0.32 | $0.12 | -62.50% | $776.1M | -0.52% |
| Q2 25 BEAT | $1.01 | $1.44 | +42.31% | $825.4M | +8.37% |
| Q1 25 BEAT | $0.95 | $1.13 | +18.87% | $745.1M | +0.91% |